Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthranilic Acid SCHEMBL28368950 | 0.79 | HIF1A (0.44) | HIF1ALMNAMAOBSMN1; SMN2TP53 | |
| SCHEMBL8103815 | 0.73 | CA12 (0.46) | HIF1ALMNACA12CA1CA2 | |
| SCHEMBL4930668 | 0.73 | CA12 (0.46) | HIF1ALMNACA12CA1CA2 | |
| SCHEMBL1839676 | 0.73 | ALDH1A1 (0.51) | HIF1ALMNAESR1ESR2SMN1; SMN2 | |
| SCHEMBL6989194 | 0.73 | FAAH (0.51) | HIF1ALMNASMN1; SMN2FAAH | |
| SCHEMBL1809709 | 0.73 | HIF1A (0.58) | HIF1A | |
| SCHEMBL2874811 | 0.71 | CA12 (0.44) | HIF1ALMNACA12CA1CA2 | |
| SCHEMBL6419652 | 0.71 | CA12 (0.44) | HIF1ALMNACA12CA1CA2 | |
| SCHEMBL605706 | 0.71 | SMN1; SMN2 (0.45) | HIF1ALMNACA12CA1CA2 | |
| SCHEMBL1887460 | 0.71 | CA12 (0.48) | HIF1ALMNACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110922368-B | Chloro-phenyl-isoxazole aminobenzoic acid derivative and preparation method and application thereof | 扬州工业职业技术学院 | 2022-08-16 | — | — | CN | claimed |
| CN-105399697-A | Amino sulfonyl compound, preparation method and uses thereof | SUZHOU WANGSHAN WANGSHUI BIOMEDICAL CO LTD | 2016-03-16 | — | — | CN | claimed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | BREYE THERAPEUTICS APS (DK) | 2026-02-10 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| US-20250170116-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | OSAKA UNIVERSITY (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250073229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | SHINSHU UNIVERSITY (JP) | 2025-03-06 | — | — | US | disclosed |
| EP-4262975-B1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2025-03-05 | — | — | EP | disclosed |
| EP-4487848-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | OSAKA UNIVERSITY (JP) | 2025-01-08 | — | — | EP | disclosed |
| US-12152038-B2 | Vasopressin receptor antagonists and products and methods related thereto | Neumora Therapeutics, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4461296-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | Osaka University (JP) | 2024-11-13 | — | — | EP | disclosed |
| EP-0573467-A1 | NEUROLEPTIC PERHYDRO-1H-PYRIDO 1,2-a]PYRAZINES. | PFIZER (US) | 1993-12-15 | — | — | EP | disclosed |
| EP-0573464-A1 | PROCESS FOR PREPARING TRANS-PIPERIDINE-2,5-DICARBOXYLATES. | PFIZER (US) | 1993-12-15 | — | — | EP | disclosed |
| WO-1993016073-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-19 | — | — | WO | disclosed |
| US-5157034-A | Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines | PFIZER INC. (US) | 1992-10-20 | — | — | US | disclosed |
| WO-1992017475-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER INC. (US) | 1992-10-15 | — | — | WO | disclosed |
| WO-1992015561-A2 | PROCESS FOR PREPARING TRANS-PIPERIDINE-2,5-DICARBOXYLATES | PFIZER INC. (US) | 1992-09-17 | — | — | WO | disclosed |
| WO-1992015580-A1 | NEUROLEPTIC PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES | PFIZER INC. (US) | 1992-09-17 | — | — | WO | disclosed |
| US-4452799-A | NEUROLEPTIC AGENTS | MEAD JOHNSON & COMPANY (US) | 1984-06-05 | — | — | US | disclosed |
| US-4411901-A | ANTIPSYCHOTICS | MEAD JOHNSON & COMPANY (US) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152038-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1A, AVPR2, AVPR1B | HIF1A 1511/4885LMNA 2281/4885CA12 2327/4885 |
| US-20250170116-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | REN, ATP6V1B1, CYP2S1 | HIF1A 630/4885LMNA 1915/4885CA12 1518/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | HIF1A 3217/4885LMNA 3274/4885CA12 906/4885 |
| US-20250073229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | CBR1, CYP2S1, CYP2F1 | HIF1A 381/4885LMNA 2530/4885CA12 1810/4885 |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | HIF1A 979/4885LMNA 1370/4885CA12 4147/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | HIF1A 2572/4885LMNA 1392/4885CA12 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.